Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf ...

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. and its board of directors concerning the proposed acquisition of the company by Alumis Inc. . Stockholders will ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company's ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...